TY - JOUR 
A1 - Henríquez, Iván
AU - Roach III, Mack
AU - Morgan, Todd M.
AU - Bossi, Alberto
AU - Gómez, Junior A.
AU - Abuchaibe, Óscar
AU - Couñago Lorenzo, Felipe
T1 - Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Y1 - 2021
SN - 2227-9059
UR - http://hdl.handle.net/11268/11378
AB - Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation. However, due to the rapidly changing therapeutic landscape in mCRPC, it is difficult for clinicians to keep up to date with the latest innovations in this area. In the present narrative review, we discuss the current and emerging therapies for mCRPC as well as the clinical and molecular factors that can help predict which patients are most likely to benefit from these novel agents.
KW - Neoplasias de la próstata resistentes a la castración
KW - Metástasis de la neoplasia
KW - Hormonas
KW - Cáncer
KW - Tratamiento médico
LA - eng
ER -